Oligonucleotide analogs with novel linkages
CA 2071483 C · Owner: Isis Pharmaceuticals Inc. · Inventors: Matteucci, Mark
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The instant invention is directed to oligonucleotide compounds wherein on or more phosphodiester linkages between adjacent nucleotides are replaced by a formacetal/ketal type linkage. The nucleotides of the present invention are resistant to nucleases and do not need to exhibit the diastereomerism characteristic of many other oligonucleotide compounds and thus are capable of strong hybridization to target RNA or DNA. These oligonucleotide compounds are useful in therapies which modulate gene expression using antisense or other specifically binding oligomers.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 24, 1990 and granted April 17, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 24, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 24, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.